Polygenic embryo screening: four clinical considerations warrant further attention
Stacey Pereira, Shai Carmi, Gheona Altarescu, Jehannine Austin, Dorit Barlevy, Avner Hershlag, Eric T. Juengst, Kristin M. Kostick, E Kovanci, Ruth B. Lathi, Meghna Mukherjee, Ignatia Van den Veyver, Or Zuk, Gabriel Lázaro‐Muñoz, Todd Lencz
Abstract
Recent advances in developing polygenic scores have made it possible to screen embryos for common, complex conditions and traits. Polygenic embryo screening (PES) is currently offered commercially, and though there has been much recent media and academic coverage, reproductive specialists' points of view have not yet been prominent in these discussions. We convened a roundtable of multidisciplinary experts, including reproductive specialists to discuss PES and its implications. In this Opinion, we describe four clinically relevant issues associated with the use of PES that have not yet been discussed in the literature and warrant consideration.